PFIZER Q4 FY25 earnings call PFE

Pfizer has defined four strategic priorities for 2026, focusing on maximizing value from recent acquisitions like Seagen, Metsera, and Biohaven, advancing key R&D milestones, investing for post-2028 growth, and scaling artificial intelligence across operations. This pivotal investment period aims to position the company for industry-leading growth despite upcoming patent expirations. The company plans to initiate approximately 20 pivotal studies in 2026, with 10 in the Metsera portfolio and four for its anti-PD-1 VEGF bispecific.

The company announced encouraging VESPER-3 study results for PF'3944, an ultra-long-acting injectable GLP-1 receptor agonist, demonstrating robust weight loss of 10% to 12.3% at week 28 with monthly dosing, and a predicted nearly 16% weight loss for a higher dose. This reinforces confidence in the Phase III monthly dosing study expected to start later in 2026, with potential approvals targeted from 2028. The broader obesity pipeline includes an ultra-long-acting amylin analog and an oral GIPR antagonist, with 20-plus obesity trials planned for 2026.

Oncology remains a key growth driver, with significant progress expected in 2026. This includes a novel integrin beta 6-targeting vedotin ADC (SV) with a key readout expected in second-line-plus non-squamous metastatic non-small cell lung cancer, which affects about 50,000 patients in the U.S. and over 200,000 globally. Additionally, a robust program for '4404, a bispecific antibody licensed from 3SBio, involves seven planned or recently started trials, including two global Phase III studies to establish it as a potential backbone therapy across multiple tumor types.

Pfizer is committed to a robust and accelerated R&D approach, planning approximately 20 pivotal studies in 2026. The company is scaling artificial intelligence across R&D, manufacturing, commercial, and patient engagement, expanding to over 1,200 GPUs to meet growing AI demand over the next two years. AI is being embedded across discovery, development, regulatory, and medical to increase productivity and accelerate timelines, while also optimizing supply planning, manufacturing, and new product launches.

The capital allocation strategy focuses on maintaining and growing the dividend, reinvesting in the business, and potential future share repurchases. The company returned $9.8 billion to shareholders via dividends in 2025 and invested $10.4 billion in internal R&D and $8.8 billion in business development transactions. Cost improvement initiatives, including the Manufacturing Optimization Program and cost realignment, are on track to deliver $7.2 billion in total net cost savings by the end of 2026, with $1.5 billion from manufacturing by end of 2027.

The integration of Seagen has progressed well, with most colleagues remaining at Pfizer and accelerated programs like Padcev and SV. This acquisition has strengthened Pfizer's oncology presence, particularly in breast, genitourinary, thoracic, gastrointestinal, and blood cancers. An additional Phase III study for Padcev is planned for later this year, aiming to potentially replace cystectomy, and SV has two Phase III studies ongoing with another planned.